AzTrials
AzTrials

Sepsis-Associated EncephalopathyNCT05451537

Correlation of Formyl Peptide Receptor 1 With Sepsis-related Encephalopathy

An observational study of Sepsis-Associated Encephalopathy, run by General Hospital of Ningxia Medical University at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The pathogenesis of sepsis-associated encephalopathy (SAE) is unclear, Formylpeptide receptor 1 (FPR1) is a cell membrane receptor that recruits leukocytes and mediates inflammatory responses after activation, but its role and mechanism in SAE are unknown. Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Sepsis-Associated Encephalopathy
How many people
100 participants
Where
1 siteChina
Study dates
1 Sep 2022to 29 Sep 2025
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Severe sepsis and septic shock, Sepsis associated encephalopathy

Who may be able to join

  • Inclusion criteria for participants were patients with an age of 18-70 years and an inclusion within 24 hours after the beginning of severe sepsis or septic shock according to the criteria that were established by the international guidelines for management of severe sepsis and septic shock.

Who cannot join

  • Patients were excluded from the study if they had a previous diagnosis of a neuropsychiatric disease (head trauma, cerebral stroke, epilepsy, and intracranial infection), current brain disorders (hepatic encephalopathy, pulmonary encephalopathy, and severe electrolyte imbalance), concurrent hematologic diseases, malignant tumor, postcardiac arrest, or melanoma or if they were undergoing cancer chemotherapy.

Trial locations and contacts

1 site in 1 country.

China1 site
  • Department of Anesthesiology, General Hospital of Ningxia Medical University

    Yinchuan, Ningxia, 750004

Other trials in China

About this study

Official title: Correlation of Formyl Peptide Receptor 1 With Sepsis-related Encephalopathy: A Prospective Cohort Study

The pathogenesis of sepsis-associated encephalopathy (SAE) is unclear, Formylpeptide receptor 1 (FPR1) is a cell membrane receptor that recruits leukocytes and mediates inflammatory responses after activation, but its role and mechanism in SAE are unknown. This project intends to clarify the relationship between FPR1 activation and SAE from the clinical. The investigators enrolled 100 patients with sepsis in ICU. Patients were divided into two groups according to diagnostic criteria: SAE group and none-SAE group. Whole blood was collected. The serum FPR1 protein level was measured using a commercial enzyme-linked immunosorbent assay. After whole blood RNA was extracted, the expressions of FPR1 and a reference gene were quantified by an automated one-step Taqman RT-PCR assay. Multiple logistical regression analysis was used to identify the independent factors (including FPR1 activation) for the prediction of SAE outcomes.

Read the detailed description

Background The pathogenesis of sepsis-associated encephalopathy (SAE) is unclear, and there are no desired therapeutic methods. Formylpeptide receptor 1 (FPR1) is a cell membrane receptor that recruits leukocytes and mediates inflammatory responses after activation, but its role and mechanism in SAE are unknown. Our previous studies have shown that the expression of FPR1 in the hippocampus of septic mice is increased; FPR1 knockout reduces mortality and microglial activation. Based on this, it is hypothesized that during sepsis, FPR1 induces the migration and recruitment of neutrophils and monocytes to the brain, at the same time, FPR1 activation of microglia mediates brain inflammatory response and cell death, these factors induces or aggravates cognitive dysfunction. This project intends to clarify the relationship between FPR1 activation and SAE from the clinical. The study will provide some useful data for the mechanism study of SAE.

Methods Inclusion criteria for participants were patients with an age of 18-70 years and an inclusion within 24 hours after the beginning of severe sepsis or septic shock according to the criteria that were established by the international guidelines for management of severe sepsis and septic shock.

Patients were excluded from the study if they had a previous diagnosis of a neuropsychiatric disease (head trauma, cerebral stroke, epilepsy, and intracranial infection), current brain disorders (hepatic encephalopathy, pulmonary encephalopathy, and severe electrolyte imbalance), concurrent hematologic diseases, malignant tumor, postcardiac arrest, or melanoma or if they were undergoing cancer chemotherapy.

Demographic, clinical, and laboratory data were retrieved after intensive care unit (ICU) admission from the medical records made by two physicians. Age, gender, Acute Physiology and Chronic Health Evaluation II score (APACHE II score), Sequential Organ Failure Assessment (SOFA) score, GCS score, and infection sites were collected and determined during the first 24 hours of admission. basic laboratory tests, including blood lactate, B-type natriuretic peptide, and inflammatory markers of white blood cell count (WBC), procalcitonin (PCT), and C-reactive protein (CRP), were detected on admission. The GCS and mental status of the patients were evaluated twice a day, at eight o'clock in the morning and six o'clock in the afternoon, including SAE symptoms of somnolence, stupor, coma, confusion, disorientation, agitation, irritability, and decreased level of GCS. Sepsis-associated encephalopathy (SAE) was defined as cerebral dysfunction in the presence of severe sepsis as well as the presentation of two or more of the symptoms listed above after complete withdrawal of sedation.

Original cerebral dysfunction derived from hypoxic encephalopathy, severe hypoglycemia, intracranial hemorrhage, epilepsy relapse, acute ischemic stroke, and hyponatremia were excluded. Supportive treatments, such as the use of a ventilator, length of ICU stay, and 28-day mortality, were also included for assessment.

Blood samples were collected from patients on admission through venipuncture. the resultant serum samples were aliquoted and stored at -80°C until further analysis. The serum FPR1 protein level was measured using a commercial enzyme-linked immunosorbent assay.

Patients were divided into two groups according to diagnostic criteria: SAE group and none SAE group. Whole blood was collected. The serum FPR1 protein level was measured using a commercial enzyme-linked immunosorbent assay. After whole blood RNA was extracted, the expressions of FPR1 and a reference gene were quantified by an automated one-step Taqman RT-PCR assay.

Multiple logistical regression analysis was used to identify the independent factors for the prediction of SAE outcomes using the forward stepwise method with the likelihood ratio test. Correlations between variables were tested by the Pearson linear regression test. Receiver operating characteristics (ROC) analysis was used to qualify marker performance, and ROC curves were constructed to assess the sensitivity, specificity, and respective areas under the curves (AUCs) of the FPR1 protein performance with 95% CI. A value of P<0.05 was considered statistically significant.

The primary outcome is the comparison of FPR1 levels in patients with and without sepsis related encephalopathy. Secondary Outcome Measures: the comparison of laboratory data, inflammatory cytokines levels in patients with and without sepsis related encephalopathy.

Medical subject headings
Sepsis-Associated Encephalopathy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT05451537
Study groupRoleWhat they receive
Sepsis associated encephalopathy groupPatients were diagnosed with sepsis related encephalopathy
None sepsis associated encephalopathy groupPatients were not diagnosed with sepsis related encephalopathy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The comparison of FPR1 levels in patients with and without sepsis related encephalopathy

    The comparison of serum FPR1 protein levels (ng/ml) in patients with and without sepsis related encephalopathy

    Measured: 3 days

Secondary outcomes (3)
  1. The comparison of Inflammatory cytokines levels in patients with and without sepsis related encephalopathy

    The comparison of serum IL-1β and IL-6 concentrations (ng/ml) in patients with and without sepsis related encephalopathy

    Measured: 3 days

  2. The comparison of peripheral blood leukocytes in patients with and without sepsis related encephalopathy

    The comparison of peripheral blood leukocytes count in patients with and without sepsis related encephalopathy

    Measured: 3 days

  3. The comparison of S-100β levels in patients with and without sepsis related encephalopathy

    The comparison of peripheral blood S-100β protein concentrations (ng/ml) in patients with and without sepsis related encephalopathy

    Measured: 3 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Jul 2022
  2. Study start1 Sep 2022 (estimated)
  3. Primary completion29 Sep 2025 (estimated)
  4. Study completion29 Sep 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05451537
Sponsor's protocol ID
KYLL-2022-0139
Status last verified
Jun 2022
First submitted
23 Jun 2022
Last updated
11 Jul 2022
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Ma G, Ma J, Qu B, Zhang C, Zhu J, Chen Y, Ma Y, Meng X. Knockout or treatment with an antagonist of formyl peptide receptor 1 protects mice from sepsis by inhibiting inflammation. Cytokine. 2025 Mar;187:156872. doi: 10.1016/j.cyto.2025.156872. Epub 2025 Jan 28.

    PubMed 39879890

Questions about this trial

What is this clinical trial studying?

An observational study of Sepsis-Associated Encephalopathy, run by General Hospital of Ningxia Medical University at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 11 Jul 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Gang Ma, doctor (13709519220 ext. +86, magang2671@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The comparison of FPR1 levels in patients with and without sepsis related encephalopathy (time frame: 3 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05451537, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jul 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in